From 2008 to 2010, VESO underwent a privatisation process through a Management Buy Out (MBO). In 2019, the government divested its entire stake, resulting in AquaNova Invest AS’s current ownership positionin VESO. The remaining shares are held by present and former employees.

Since the privatisation, VESO has experienced remarkable growth, with more than eightfold increased turnover. The substantial increase represents an average annual growth rate of >14%. VESO’s success can be attributed to several factors, including heightened market penetration, expansion within the fish and animal health sectors in Norway, strategic investments in new ventures, novel markets entries, and the introduction of innovative products and services. 

Between 2007 and 2015, VESO allocated substantial resources towards the development of a breeding and genetics enterprise. Recognising the need for continued growth and expansion, VESO made a strategic decision to divest this business to Benchmark Holding in 2015.

In 2016, VESO acquired a controlling interest (51%) in Brynsløkken AS, a company engaged in the development and manufacturing of antifouling and other chemical products. Since the acquisition, the company has exhibited substantial growth and advancement, establishing a prominent position as one of the leading suppliers in the industry.

In recent years, the organisation has expanded within within the domains of animal and fish health. In addition to vaccines and pharmaceuticals, we have successfully broadened our offerings through strategic collaborations with pioneering and renowned international manufacturers. We have introduced a range of new products, including hygiene solutions, veterinary consumables, dietary supplements, and microbial products.